HealthQuill Hepatitis B
US regulator, the FDA has approved Gilead Sciences, Inc.'s supplemental new drug application for treating chronic hepatitis B virus in paediatric patients six years of age and older.
Drugs Health Pharma

FDA nod for Gilead to expand hepatitis drug to six years or older patients

HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.

Read More
Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival for its investigational therapy to treat liver cancer.
Drugs Health Pharma

Bristol Myers says liver cancer therapy trial improves overall survival rate

HQ Team March 20, 2024: Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival.

Read More
GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights to develop and commercialise the US company’s hepatitis B therapy.
Drugs Health Pharma

GSK to pay $1 billion to acquire exclusive rights for J&J hepatitis B therapy

 HQ Team November 1, 2023: GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights.

Read More
X